

DEINOVE LAUNCHES THE INDUSTRIAL PRODUCTION OF ITS FIRST CAROTENOID

- **Deinove's production process gaining momentum: fermentation scale-up is planned at the BIOGIS Center, SAS PIVERT's technological platform**
- **Technology transfer and production of the first pilot batches are under way**
- **Objectives: first industrial batches in the first quarter of 2018 and commercial launch of the actual cosmetic ingredient during the second quarter of 2018**

Montpellier, 18 December 2017 (6:30pm CET) – DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria, notably from the *Deinococcus* genus, **announces the launch of the industrial production of its first carotenoid.** The company's fermentation platform has developed an optimized process in terms of performance and robustness on a 20-liter scale. At the same time, the collaboration with Processium lead to the definition of the downstream process of extraction, purification, and formulation, and the drafting of the "Process Book" detailing its implementation. To ensure future commercialization, SAS PIVERT was selected as a partner to take over the fermentation on an industrial scale. Technology transfer is underway and production on a scale of several cubic meters will start in January. The fermentation step will be followed by that of extraction, purification, and formulation. Several batches will be produced to validate the industrial process, and sampled for the commercial effort that will begin in the second quarter.

In parallel, DEINOVE conducted a comprehensive program to demonstrate the safety of the strain involved in the production process of the ingredient, *Deinococcus geothermalis*. The tests were conducted on a GRAS self-affirmation scheme - a US-specific regulatory approach - and are in line with OECD guidelines and the demands of both European and US regulatory authorities. These studies have been successfully concluded and show a total absence of toxicity of the producing strain. These very satisfactory results offer promising prospects for marketing the various compounds manufactured by this strain, including carotenoids, in the field of cosmetics and also nutrition.

Marie BÉZINGER, VP Operations at DEINOVE, said: *"We are about to produce our first ingredient on an industrial scale. Our teams are on-site to ensure the transfer of technology and we are looking forward to seeing what comes out of the first batches. This is a first for Deinove and one of the last steps before the commercialization of our innovative ingredient."*

ABOUT DEINOVE

DEINOVE (Euronext Growth Paris: ALDEI) is a biotech company that discovers, develops and produces high added-value compounds from rare microorganisms for use in the fields of health, nutrition and cosmetic markets.

To do so, DEINOVE draws on two key assets:

- a unique library of 6,000 rare or unexploited bacterial strains, mainly of the *Deinococcus* genus;
- a genetic, metabolic and fermentation engineering platform capable of customizing these natural "micro-factories" to transform them into new industrial standards.

Based in Montpellier, DEINOVE employs approximately 55 employees and has nearly 160 international patents. The Company has been listed on Euronext Growth since April 2010.

Contact details

Emmanuel Petiot

Chief Executive Officer

Tel: +33 (0)4 48 19 01 28

emmanuel.petiot@deinove.com

Coralie Martin

Communication, Marketing and Investor Relations

Tel: +33 (0)4 48 19 01 60

coralie.martin@deinove.com

ALIZE RP, Press Relations

Caroline Carmagnol / Wendy Rigal

Tel: +33 (0)1 44 54 36 66

deinove@alizerp.com

ALDEI

**EURONEXT
GROWTH**



www.deinove.com



twitter.com/Deinove



fr.linkedin.com/company/deinove